Deutsche Biotech Innovativ Past Earnings Performance
Past criteria checks 0/6
Deutsche Biotech Innovativ's earnings have been declining at an average annual rate of -5.9%, while the Biotechs industry saw earnings growing at 17.7% annually.
Key information
-5.9%
Earnings growth rate
-5.9%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | n/a |
| Return on equity | -34.7% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2022 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Deutsche Biotech Innovativ makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 22 | 0 | 0 | 0 | 0 |
| 31 Dec 21 | 0 | 0 | 0 | 0 |
| 31 Dec 20 | 0 | 0 | 0 | 0 |
| 30 Jun 20 | 0 | 0 | 0 | 0 |
| 31 Mar 20 | 0 | 0 | 0 | 0 |
| 31 Dec 19 | 0 | 0 | 0 | 0 |
| 30 Sep 19 | 0 | 0 | 0 | 0 |
| 30 Jun 19 | 0 | 0 | 0 | 0 |
| 31 Mar 19 | 0 | 0 | 0 | 0 |
| 31 Dec 18 | 0 | 0 | 0 | 0 |
| 30 Sep 18 | 0 | 0 | 0 | 0 |
| 30 Jun 18 | 0 | 0 | 0 | 0 |
| 31 Mar 18 | 0 | 0 | 0 | 0 |
| 31 Dec 17 | 0 | 0 | 0 | 0 |
| 30 Sep 17 | 0 | 0 | 0 | 0 |
| 30 Jun 17 | 0 | 0 | 0 | 0 |
| 31 Mar 17 | 0 | 0 | 0 | 0 |
| 31 Dec 16 | 0 | 0 | 0 | 0 |
| 30 Sep 16 | 0 | 0 | 0 | 0 |
| 30 Jun 16 | 0 | 0 | 0 | 0 |
| 31 Mar 16 | 0 | -1 | 0 | 0 |
| 31 Dec 15 | 0 | -1 | 0 | 0 |
| 30 Sep 15 | 0 | 0 | 0 | 0 |
| 30 Jun 15 | 0 | 0 | 0 | 0 |
| 31 Mar 15 | 0 | 0 | 0 | 0 |
| 31 Dec 14 | 0 | 0 | 0 | 0 |
Quality Earnings: DBI is currently unprofitable.
Growing Profit Margin: DBI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if DBI's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare DBI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DBI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).
Return on Equity
High ROE: DBI has a negative Return on Equity (-34.7%), as it is currently unprofitable.